ObsEva price target raised to $44 from $30 at H.C. Wainwright. H.C. Wainwright analyst Raghuram raised his price target for ObsEva (OBSV) to $44 based on the disclosed pricing for AbbVie’s (ABBV) Orilissa, the fgonadotropin-releasing hormone receptor antagonist for endometriosis and uterine fibroids. ObsEva management had previously guided to the cost of GnRH receptor antagonist therapy at $15 per day, about $450 per month, and the proposed monthly cost of Orilissa at $845 “appears to be comfortably above this level,” Selvaraju tells investors in a research note. As such, the analyst elected to revise his pricing assumptions upward for ObsEva’s linzagolix to reflect a daily cost of $25. He keeps a Buy rating on ObsEva shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.